Cardiotoxicity of cancer therapy is increasingly recognized as a critical determinant of long-term clinical outcome. However, evidence on cardiac structural and hemodynamic effects of oncological treatment in patients with hypertrophic cardiomyopathy (HCM) remains scarce.
The aim of our study was to evalua...
T. Zou, J. Geske, J. Herrmann· European Heart Journal· 0 citations
Hypertrophic cardiomyopathy (HCM) is a common inherited cardiac disorder. While most patients remain free of ventricular arrhythmia events (VAEs), a small subset experiences recurrent episodes. The clinical profile of these patients remains poorly characterized.
This longitudinal, long-term follow-up study...
O. Galvin, A. Arruda-Olson, V. Vizentin et al.· European Heart Journal· 0 citations
Abstract Hypertrophic cardiomyopathy is a common heritable heart disease. The disease is genetically, anatomically, and clinically heterogeneous. Hypertrophic cardiomyopathy is inherited in an autosomal dominant pattern but has allelic heterogeneity, incomplete penetrance, and variable expressivity. Beyond family scree...
Kendra Gilreath, D. Newman, S. Ommen et al.· BMJ Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.